These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3526070)

  • 1. Effects of hypersecretion of growth hormone and prolactin on plasma levels of glucagon and insulin in GH3-cell-tumor-bearing rats, and the influence of bromocriptine treatment.
    Knudtzon J; Johansen PW; Haug E; Gautvik K
    Life Sci; 1986 Aug; 39(7):617-21. PubMed ID: 3526070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bromocriptine, ergotamine and other ergot alkaloids on the hormone secretion and growth of a rat pituitary tumour.
    Prysor-Jones RA; Jenkins JS
    J Endocrinol; 1980 Jul; 86(1):147-53. PubMed ID: 7430884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal and morphologic effects of bromocriptine on normal rat pituitary and GH3 tumor cells.
    Lahteenmaki P; Marrs RP; Schechter J; Zacharias S; Kletzky OA
    Am J Obstet Gynecol; 1985 Oct; 153(4):349-57. PubMed ID: 4050909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients.
    Fedele D; Molinari M; Meneghel A; Valerio A; Muggeo M; Tiengo A
    J Endocrinol Invest; 1980; 3(2):149-53. PubMed ID: 6993548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone, insulin, and prolactin secretion in anorexia nervosa and obesity during bromocriptine treatment.
    Harrower AD; Yap PL; Nairn IM; Walton HJ; Strong JA; Craig A
    Br Med J; 1977 Jul; 2(6080):156-9. PubMed ID: 577473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of prolonged bromocriptine administration on PRL secretion GH and glycaemic control in stable insulin-dependent diabetes mellitus.
    Scobie IN; Kesson CM; Ratcliffe JG; Maccuish AC
    Clin Endocrinol (Oxf); 1983 Feb; 18(2):179-85. PubMed ID: 6342861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromocriptine-induced dissociation of hyperglycemia and prolactin response to restraint.
    Ribeiro-de-Oliveira A; Guerra RM; Fóscolo RB; Marubayashi U; Reis AM; Coimbra CC
    Pharmacol Biochem Behav; 2001 Feb; 68(2):229-33. PubMed ID: 11267627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat.
    Uvnäs-Moberg K; Ahlenius S; Alster P; Hillegaart V
    Neuroendocrinology; 1996 Mar; 63(3):269-74. PubMed ID: 8677015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of long term bromocriptine treatment on glucose intolerance in acromegaly.
    Chiba T; Chihara K; Minamitani N; Goto B; Kadowaki S; Taminato T; Matsukura S; Fujita T
    Horm Metab Res; 1982 Feb; 14(2):57-61. PubMed ID: 7040191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased glucagon receptors in chronically hypersomatotrophic and hyperglucagonemic rats.
    Dunbar JC; Brown P; Dixon S
    Proc Soc Exp Biol Med; 1985 May; 179(1):32-7. PubMed ID: 2986149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon secretion in rats bearing a growth hormone producing tumor (MtT-W-15).
    Dunbar JC; Walsh MF
    Diabete Metab; 1978 Dec; 4(4):249-53. PubMed ID: 365650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of bromocriptine on experimental GH3 cell tumors.
    Kamijo K; Sato M; Saito T; Yachi A; Minase T
    Pathol Res Pract; 1991 Jun; 187(5):593-7. PubMed ID: 1923956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gluconeogenesis in the tumor-influenced rat hepatocyte: importance of tumor burden, lactate, insulin, and glucagon.
    Inculet RI; Peacock JL; Gorschboth CM; Norton JA
    J Natl Cancer Inst; 1987 Nov; 79(5):1039-46. PubMed ID: 3316783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity.
    Maccario M; Grottoli S; Procopio M; Oleandri SE; Barberis A; Ciccarelli E; Camanni F; Ghigo E
    J Endocrinol Invest; 1996 Apr; 19(4):219-23. PubMed ID: 8862501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bromocriptine on maturity onset diabetes.
    Barnett AH; Chapman C; Gailer K; Hayter CJ
    Postgrad Med J; 1980 Jan; 56(651):11-4. PubMed ID: 6992131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 2-bromo-alpha-ergocryptine on beta-endorphin-induced growth hormone, prolactin and luteining hormone release in urethane anesthetized rats.
    Takahra J; Kageyama J; Yunoki S; Yakushiji W; Yamauchi J; Kageyama N; Ofuji T
    Life Sci; 1978 Jun; 22(24):2205-7. PubMed ID: 672457
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulation of the hepatic response to glucagon: role of insulin, growth hormone and cortisol.
    Dunbar JC; Schultz S; Houser F; Walker J
    Horm Res; 1989; 31(5-6):244-9. PubMed ID: 2693309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon binding to liver membranes of Mt-T-W15 tumor-bearing and hypophysectomized rats. A possible role for insulin and growth hormone.
    Walsh MF; Dunbar JC
    Diabetes; 1984 Oct; 33(10):978-83. PubMed ID: 6090248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tamoxifen on growth and prolactin secretion of rat pituitary tumours.
    Prysor-Jones RA; Silverlight JJ; Jenkins JS
    J Endocrinol; 1983 May; 97(2):261-6. PubMed ID: 6854193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phorbol esters affect pituitary growth hormone (GH) and prolactin release: the interaction with GH releasing factor, somatostatin and bromocriptine.
    Summers ST; Canonico PL; MacLeod RM; Rogol AD; Cronin MJ
    Eur J Pharmacol; 1985 May; 111(3):371-6. PubMed ID: 2862049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.